• Susanne Perkhofer and Cornelia Lass-Flörl.
• Innsbruck Medical University, Department of Hygiene, Microbiology and Social Medicine, Fritz-Pregl Str. 3, A-6020 Innsbruck, Austria. Susanne.Perkhofer@i-med.ac.at
• Expert Opin Investig Drugs. 2009 Sep 1; 18 (9): 1393-404.

AbstractThe incidence of invasive fungal infections has been increasing since the 1980s due to a growing population of immunocompromised and critically ill patients with associated risk factors including immunosuppressive chemotherapy, prolonged periods on intensive care units and infection with HIV. Persons who are severely immunocompromised are particularly vulnerable to infection from molds and yeasts that are often found naturally in the environment. In recent years, several new systemic antifungal agents have been released, significantly increasing options for the treatment of the most serious fungal infections. Newly available drugs as those in the echinocandin class include caspofungin, micafungin and anidulafungin, as well as the newer generation triazoles, voriconazole and posaconazole. In this review, the in vitro and in vivo activity of anidulafungin and voriconazole, both new antimycotic substances with a different mode of action, are analyzed.

33 keywords...

hide…